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Cellular/Molecular
Proteasome Inhibition Stabilizes Tau Inclusions in
Oligodendroglial Cells that Occur after Treatment with
Okadaic Acid
Olaf Goldbaum,1 Malte Oppermann,1 Melanie Handschuh,1 Deepa Dabir,2 Bin Zhang,2 Mark S. Forman,2
John Q. Trojanowski,2,3 Virginia M.-Y. Lee,2 and Christiane Richter-Landsberg1
1University of Oldenburg, Department of Biology, Molecular Neurobiology, D-26111 Oldenburg, Germany, and 2Center for Neurodegenerative Disease
Research, Department of Pathology and Laboratory Medicine, and 3Institute on Aging, University of Pennsylvania School of Medicine, Philadelphia,
Pennsylvania 19104
Tau-positive inclusions in oligodendrocytes are consistent neuropathological features of corticobasal degeneration, progressive su-
pranuclear palsy, and frontotemporal dementias with Parkinsonism linked to chromosome 17. Here we show by immunohistochemistry
that tau-positive oligodendroglial inclusion bodies also contain the small heat-shock protein (HSP) B-crystallin but not HSP70. To study
the molecular mechanisms underlying inclusion body formation, we engineered an oligodendroglia cell line (OLN-t40) to overexpress the
longest human tau isoform. Treatment of OLN-t40 cells with okadaic acid (OA), an inhibitor of protein phosphatase 2A, caused tau
hyperphosphorylation and a decrease in the binding of tau to microtubules. Simultaneously, tau-positive aggregates that also stained
with the amyloid-binding dye thioflavin-S as well as with antibodies to tau and B-crystallin were detected. However, they were only
transiently expressed and were degraded within 24 hr. When the proteasomal apparatus was inhibited by carbobenzoxy-L-leucyl-L-leucyl-
L-leucinal (MG-132) after OA treatment, the aggregates were stabilized and were still detectable after 18 hr in the absence of OA. Incuba-
tion with MG-132 alone inhibited tau proteolysis and led to the induction of HSPs, including B-crystallin and to its translocation to the
perinuclear region, but did not induce the formation of thioflavin-S-positive aggregates. Hence, although tau hyperphosphorylation
induced by protein phosphatase inhibition contributes to pathological aggregate formation, only hyperphosporylation of tau followed by
proteasome inhibition leads to stable fibrillary deposits of tau similar to those observed in neurodegenerative diseases.
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Introduction
Intracellular accumulations of the microtubule (MT)-associated
protein tau are the defining neuropathological characteristics of
Alzheimer’s disease (AD), and they also occur in a variety of
dementias and movement disorders collectively named tauopa-
thies (Lee et al., 2001). In AD, fibrillary tau accumulations pref-
erentially form in nerve cells, but abundant neuronal and glial
filamentous tau inclusions are prominent in familial multiple
system tauopathy, which belongs to a group of frontotemporal
dementias with Parkinsonism linked to chromosome 17 (FTDP-
17) (Goedert et al., 1998). Tau-positive glial inclusions are con-
sistent features in the brains of patients with FTDP-17, progres-
sive supranuclear palsy (PSP), and corticobasal degeneration
(CBD) (Chin and Goldman, 1996; Goedert et al., 1998; Komori,
1999; Berry et al., 2001). Oligodendroglial lesions and white-
matter pathology are characterized by the occurrence of glial
fibrillary tangles or “coiled bodies” containing tau, and tau as well
as -synuclein-positive glial cytoplasmic inclusions (GCIs) in ol-
igodendroglia are the histological hallmarks of multiple system
atrophy (MSA). GCIs are composed of a meshwork of loosely
packed filaments and stained with antibodies against tau, ubiq-
uitin, -synuclein, and the small heat-shock protein (HSP) B-
crystallin, although -synuclein is the major building block of
these inclusions (Chin and Goldman, 1996; Tu et al., 1998;
Komori, 1999).
Oligodendrocytes are rich in MTs and express tau (Gorath et
al., 2001). Tau is abundant in the CNS and modulates MT stabil-
ity and organization. The molecular mechanisms leading to the
formation of insoluble aggregates of tau, which under normal
conditions is a highly soluble protein, are not yet resolved. Al-
though tau hyperphosphorylation might be a prerequisite for
aggregate formation, evidence has accumulated suggesting that
hyperphosphorylation is not directly responsible for pathological
aggregation of tau and cell death (Schneider et al., 1999), thus
indicating that other factors might contribute to the formation of
neurofibrillary tau pathology.
Protein aggregates do not accumulate in healthy, unstressed
cells, and HSPs act as molecular chaperones and prevent the ag-
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gregation or accumulation of abnormal proteins (Sherman and
Goldberg, 2001). If this protective mechanism fails, misfolded
proteins are ubiquitinated and degraded by the proteasomal ma-
chinery (Schwartz and Ciechanover, 1999). Inclusion bodies or
aggregates are formed when the protein degradation machinery is
exceeded or impaired. Small aggregates can be sequestered
around the MT-organizing center, because of MT-dependent
retrograde transport, and assemble to large aggresomes, which
are also enriched in molecular chaperones (Johnston et al., 1998;
Kopito, 2000).
In the present study, we show by immunohistochemistry that
inclusion bodies in oligodendrocytes of the brains of patients
with CBD, PSP, or FTDP-17, which are
formed by tau filaments rather than
-synuclein, are also positively labeled
by antibodies against the small HSP B-
crystallin, whereas HSP70 is not detectable.
To investigate whether tau hyperphosphory-
lation is a necessary requirement for the
formation of cytoplasmic aggregates in glia
cells, we examined the effects of the protein
phosphatase 2A (PP2A) inhibitor okadaic
acid (OA) on transfected oligodendroglia
cell line OLN-93 cells that were engineered
to stably express the longest human tau iso-
form. OA leads to the transient formation of
thioflavin S-positive cytoplasmic inclusions,
which can be stabilized by the proteasome
inhibitor carbobenzoxy-L-leucyl-L-leucyl-L-
leucinal (MG-132). Our studies show that
these experimentally induced oligodendro-
glial inclusion bodies are associated with tau
aggregate formation, and that they also accu-
mulate the small HSP B-crystallin as ob-
served in authentic coiled bodies in the
brains of patients with tauopathies.
Materials and Methods
Materials and antibodies. Cell culture media
were purchased from Invitrogen (Grand Island,
NY). Okadaic acid, MG-132, and proteolytic
substrates Z-Leu-Leu-Glu-AMC (S2) and Suc-
Leu-Leu-Val-Tyr-AMC (S3) were purchased
from Calbiochem (Bad Soden, Germany). Lith-
ium chloride, Taxol, GTP, and ATP were pur-
chased from Sigma (St. Louis, MO).
For Western blot analysis, the following
panel of tau antibodies and the working
dilutions were used, as described previously
(Vogelsberg-Ragaglia et al., 2000): tau 17026 (1:
2000), a phosphorylation-independent rabbit
polyclonal antibody made against the largest
human recombinant tau; monoclonal antibody
(MAb) tau-1 (1:1000), specific for nonphos-
phorylated epitope located in amino acid resi-
dues 189 –209; MAb PHF-1 (1:500; generously
provided by Peter Davies, Albert Einstein Col-
lege of Medicine, Bronx, NY), specific for phos-
phorylated serine 396/404; and MAb 12E8 (1:
250), specific for phosphorylated serine 262.
The anti--tubulin MAb (1:1000) was obtained
from Sigma. HRP-conjugated anti-mouse IgG
was obtained from Amersham Biosciences
(Freiburg, Germany), and anti-rabbit IgG was
obtained from Bio-Rad (Munich, Germany).
Polyclonal anti-B-crystallin (1:500), poly-
clonal anti-HSP32/HO-1 (1:1000), polyclonal anti-HSP40 (1:1000),
MAb anti-HSP60 (1:1000), MAb anti-HSP70 (1:1000), MAb anti-HSP/
HSC70 (1:1000), and MAb anti-HSP90 (1:1000) were obtained from
StressGen (Victoria, Canada). Antibodies to the proteasome subunits
anti-20S (1:1000) and anti-20S (1:1000) were purchased from
Calbiochem.
Histochemistry and immunohistochemistry. The human tissue was fixed
in 10% formalin, paraffin-embedded, and cut into 6 m thick sections.
Immunohistochemistry was performed as described previously
(Schmidt et al., 1987) using the ABC method (Vectastain ABC Kit; Vec-
tor Laboratories, Burlingame, CA) and 3, 3-diaminobenzidine (DAB) as
chromogen. The following primary antibodies were used: MAb B-
Figure 1. Colocalization of tau and B-crystallin in oligodendrocytes from patients with tauopathies. A–L, Immunohisto-
chemistry on sections from the globus pallidus of CBD (A, E, I ), PSP (B, F, J ), FTDP-17 (C, G, K ), and schizophrenia (D, H, L) brains
were stained with antibodies to PHF-1 ( A–D), B-crystallin ( E–H), and HSP70 ( I–L). Insets show high-power magnification of
tau pathology ( A–C) and B-crystallin staining ( E–G) in oligodendrocytes obtained from adjacent sections. Note the abundant
tau pathology in the brains of patients with CBD, PSP, FTDP-17 ( A–C), and B-crystallin immunoreactivity ( E–G), respectively,
which was not observable in sections of schizophrenia brains (D, H ). Only baseline levels of the inducible HSP70 could be detected
( I–L). Double-immunofluorescence staining of the globus pallidus from a CBD brain shows the individual labeling of tau ( M ) and
B-crystallin ( N) as well as the colocalization of both (O, arrowheads). Staining was performed with polyclonal rabbit anti-tau
antibody N-tau (green) and MAb anti-B-crystallin antibody (red). Scale bars: A–H, M–O, 50 m; I–L, 100 m.
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crystallin (1:2500), HSP70 (1:200), and PHF-1 (1:2000). Double-labeling
immunofluorescence studies were performed by coincubating sections
with antibodies specific for N-tau and B-crystallin. N-tau is a rabbit
polyclonal antibody generated by immunizing rabbits with the synthetic
peptide AEPRQEFEVMEC, which corresponds to the amino terminal 12
amino acids (Babco, Richmond, CA). After extensive washes, sections
were labeled using AlexaFluor 488 and 594-conjugated secondary anti-
bodies (Molecular Probes, Eugene, OR) and washed and mounted using
Vectashield-4,6-diamidino-2-phenylindole (DAPI)-mounting me-
dium (Vector Laboratories). The sections were viewed with an Olympus
PX51 microscope (Olympus Optical, Tokyo, Japan) equipped with
bright-field and fluorescence light sources. Both bright-field and fluores-
cent images were obtained from the same field using a ProGres C14
camera (Laser Optik System; Jenoptik, Jena, Germany).
Stable expression of the longest human tau isoform (T40) in transfected
OLN-93 cells. OLN-93 cells were kept in DMEM supplemented with 10%
heat-inactivated fetal calf serum, 2 mM glutamine, 50 U/ml of penicillin,
and 50 g/ml of streptomycin (Richter-Landsberg and Heinrich, 1996).
OLN-93 cells were cotransfected with tau40 cDNA and pcDNA3 con-
taining the neomycin gene by using the calcium phosphate precipitation
method (Chen and Okayama, 1987). After selection in DMEM contain-
ing 1 mg/ml of G418, the cells were screened for tau expression by West-
ern blot and indirect immunofluorescence. A stable cell line was estab-
lished, designated OLN-t40, and used in the studies reported below.
Immunoblot analysis. Cellular monolayers of control and treated cells
were washed with PBS once, scraped off in sample buffer containing 1%
SDS, and boiled for 10 min. Protein contents in the samples were deter-
mined according to Neuhoff et al. (1979). For immunoblotting, total
cellular extracts (5–20 g of protein per lane) were separated by one-
dimensional SDS-PAGE using 7.5 or 12.5% polyacrylamide gels and
transferred to nitrocellulose membranes (0.45 m; Schleicher & Schuell,
Dassel, Germany) according to Towbin et al. (1979). The blots were
saturated with TBS-T (20 mM Tris, pH 7.5, 136.8 mM NaCl, 0.1% v/v
Tween 20) containing 5% dry milk and incubated with the individual
antibodies overnight at 4°C. After washing, incubation with HRP-
conjugated anti-mouse (1:2000) or anti-rabbit IgG (1:5000) was per-
formed for 1 hr, and blots were visualized by the enhanced chemilumi-
nescence procedure as described by the manufacturer (Amersham
Biosciences). All experiments were performed at least three times with
similar results.
Measurement of proteasome activity. Proteasome activity was deter-
mined using a fluorescence assay (Keller et al., 2000). Chymotrypsin- and
postglutamyl-peptidase-hydrolase peptide hydrolyzing activities were
assayed by fluorimetric measurement of the release of 7-amido-4-
methylcoumarin (AMC) from two synthetic substrates: Z-Leu-Leu-Glu-
AMC (proteasome substrate II, S2) and Suc-Leu-Leu-Val-Tyr-AMC
(proteasome substrate III, S3) at 37°C for 60 min. S2 was used for deter-
mination of the postglutamyl-peptidase-hydrolase function, and S3 was
used for the chymotrypsin-like peptidase function of the proteasome.
OLN-t40 cells were treated as described and harvested in ice-cold prote-
olysis assay buffer containing 10 mM Tris-HCl, pH 7.2, 0.035% SDS, 5
mM MgCl2, and 5 mM ATP. Protein concentrations of the resulting lysates
were determined by the bicinchoninic acid method (Pierce, Rockford,
IL) using bovine serum albumin as a standard. Aliquots of 350 l each,
with a protein concentration of 1 g/l, were incubated with 3.5 l of S2
or S3 (5 mM) for 30 min at 37°C. Fluorescence was determined at 15 min
intervals for 1 hr at 360nm excitation and 410nm emission in a fluores-
cent microplate reader (FluoroCount; Packard, Meridian, CT). Protea-
somal activity was determined as an increase in fluorescence of the reac-
tion products.
MT-binding assay of tau from OLN-t40 cells. To determine whether OA
Figure 2. Effect of okadaic acid on tau phosphorylation and heat-shock protein expression.
OLN-t40 cells were treated with 20 nM OA for the indicated times. Lysates of control (Co) and
OA-treated cells were prepared and subjected to immunoblot analysis using phosphorylation-
independent antibody 17026 reacting with total tau, and phosphorylation-dependent antibod-
ies 12E8, Tau-1, and PHF-1, recognizing nonphosphorylated and phosphorylated tau proteins,
respectively, and MAb anti--tubulin antibodies. Heat-shock proteins were identified by anti-
bodies reacting with HSP/HSC70, HSP32, and B-crystallin, respectively.
Figure 3. Okadaic acid decreases the binding of tau to microtubules in OLN-t40 cells. Cells
were treated with OA or LiCl as indicated for 24 hr. Cell lysates were separated into cytoskeletal
(P) and soluble (S) fractions after MT assembly and subjected to immunoblot analysis using
polyclonal tau 17026 and MAb anti--tubulin antibodies. OA leads to the detachment of tau
from the MTs, as indicated by an increase of tau in the soluble fraction and a decrease in the
cytoskeletal fraction. LiCl increases the binding affinity of tau to MTs, as indicated by an increase
of tau in the cytoskeletal fraction.
Figure 4. Okadaic acid leads to thioflavin-S-positive aggregates in OLN-t40 cells. Control
(a– c) cells and cells treated with 20 nM OA for 3 hr (d–f ) or 6 hr ( g–i) were subjected to indirect
immunofluorescence staining using polyclonal anti-tau 17026 antibodies, followed by staining
with thioflavin-S. For nuclear staining (blue), DAPI was included in the mounting medium. Scale
bar, 20 m.
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(5–20 nM) or lithium chloride (20 mM) alters the interaction of tau with
tubulin in the MTs of intact cells, an MT-binding assay was performed as
described previously (Bramblett et al., 1993; Merrick et al., 1997). In
brief, OLN-t40 cells were harvested in high-salt reassembly buffer (0.1 M
Tris, 0.5 mM MgSO4, 1 mM EGTA, 2 mM dithiothreitol, and 0.75 M NaCl,
pH 6.8) supplemented with 0.1% Triton X-100, 20 M Taxol, 2 mM GTP,
and a mixture of protease inhibitors (2 mM phenylmethylsulfonyl fluo-
ride, L-1-chloro-3-(4-tosylamido)-4-phenyl-2-butanon, L-1-chloro-3-
(4-tosylamido)-7-amino-2-heptanone-hydrochloride, leupeptin, pep-
statin, and soy bean trypsin inhibitor; each at 1 g/ml) at 37°C. Cell
lysates were homogenized with 15 strokes in a warm Dounce homoge-
nizer and then immediately centrifuged for 20 min at 50,000  g at 25°C.
The supernatant (S) containing unbound tau was removed, and the pro-
tein concentration was determined. The remaining pellet (P) was resus-
pended in a 2 volume of sample buffer corresponding to the total
volume of supernatant after normalizing to total protein. The samples
were subjected to immunoblot analysis as above. The ratio of tau bound
to MTs (P) versus soluble or unbound tau (S) was assessed by comparing
the tau immunoreactivities in these two fractions.
Immunofluorescence. Cells were cultured on poly-L-lysine-coated glass
coverslips (2  10 4 cells per 35 mm dish) for 24 hr in DMEM/10% FCS
followed for 3 d in DMEM/0.5% FCS and then subjected to OA or MG-
132 as indicated. After washing with PBS, cells were fixed with 3% para-
formaldehyde and permeabilized with 0.1% Triton X-100 for 15 min.
The coverslips were washed three times and incubated overnight at 4°C
with rabbit polyclonal anti-tau (17026) antibodies (1:1000) or mouse
MAb -crystallin (1:100) or PHF-1 (1:100) antibodies. After washing
with PBS, cells were incubated for 1 hr with tetramethylrhodamine
isothiocyanate-conjugated (1:100) and FITC-conjugated (1:100) sec-
ondary antibodies (Jackson ImmunoResearch, West Grove, PA), washed
with PBS, and mounted. Nuclei were stained by including DAPI (1 g/
ml) to the mounting medium. Fluorescent labeling was studied using a
Zeiss (Oberkochen, Germany) epifluorescence microscope equipped
with a digital camera using a plan-neofluar objective (100).
Thioflavin-S staining. Cells were fixed and subjected to indirect immu-
nofluorescence staining as described above. Before mounting, coverslips
were immersed in thioflavin-S solution (0.005%) for 5 min. Thereafter,
cells were washed three times in ethanol (70%), one time in water, and
then mounted.
Immunoelectron microscopy of OLN-t40 cells. Immunoelectron micros-
copy (immuno-EM) was performed on representative samples of OLN-
t40 cells expressing wild-type tau after fixation with 4% paraformalde-
hyde and 0.25% glutaraldehyde in PBS as described previously
(Vogelsberg-Ragaglia et al., 2000). The anti-tau antiserum 17026 (dilu-
tion, 1:500) in 0.1% BSA and PBS was used as the primary antibody, and
biotinylated goat anti-rabbit IgG (1:100; Vector Laboratories) was used
as a secondary antibody. DAB plus silver-gold enhancement (Nano-
probes, Yaphank, NY) immuno-EM method was conducted as described
previously (Vogelsberg-Ragaglia et al., 2000). After visualizing the DAB-
positive cells labeled by routine immuno-EM methods, silver-gold inten-
sification was performed, and the cells were examined with a JEM1010
electron microscope (Jeol, Peabody, MA) at 80 kV.
Results
Tau-positive inclusions in oligodendrocytes of brains from
patients with tauopathies
Immunohistochemical analysis of sections of the globus pallidus
from the brains of patients with CBD, PSP, and FTDP-17 was
performed using antibodies against PHF-1, HSP70, and B-
crystallin, respectively, and was compared with the globus palli-
dus of age-matched control patients with the clinical diagnosis of
schizophrenia. Sections of CBD, PSP, and FTDP-17 brains re-
vealed abundant tau-positive pathology (Fig. 1A--C). Adjacent
sections showed intense B-crystallin staining, which was specif-
ically observed in oligodendroglia (Fig. 1E--G). The cells are
characterized by their scant cytoplasm and inconspicuous
cellular processes as well as small round nuclei, and the inclu-
sions referred to as coiled bodies are identified as intensely
tau-positive cytoplasmic aggregates that often exhibit a fibril-
lary appearance by light microscopy (Komori, 1999). No
coiled bodies were observable in sections derived from the
brain of a schizophrenia patient (Fig. 1D,H), and in all samples,
only some baseline staining was seen for HSP70, which represents
the inducible form of the HSP70 family of HSPs (Fig. 1 I--L).
Double-immunofluorescence labeling also confirms the colocal-
ization of tau and B-crystallin in coiled bodies in the globus
pallidus of a CBD patient (Fig. 1M,N, arrows). Thus, oligo-
dendrocytes in tauopathy brains harbor tau-positive inclusion
bodies, which are associated with B-crystallin.
Okadaic acid induces tau hyperphosphorylation, a reduction
in tau-MT-binding capacity, and the occurrence of thioflavin-
S-positive inclusions
To explore the mechanisms underlying oligodendroglia-
inclusion body formation, OLN-t40 cells were established, a sta-
Figure 5. Inhibition of proteasome activity by MG-132 occurs without decreasing the levels
of proteasomal subunits. a, OLN-t40 cells were incubated with increasing concentrations of
MG-132 as indicated for 4 hr, and postglutamyl-peptidase-hydrolase and chymotrypsin-like
proteasome activity were determined using fluorogenic substrate S2 and S3, respectively (see Mate-
rials and Methods for details). The cleavage of both substrates is inhibited by MG-132 in a
concentration-dependent manner. Data are expressed as a percentage of the untreated control and
represent the means of three independent experiments. b, Immunoblot analysis of proteasome sub-
units. OLN-t40 cells were incubated with increasing concentrations of MG-132 as
indicated for 18 hr. Cell lysates were prepared and immunoblot analysis was performed using anti-
bodies against the proteasome subunit 20S and 20S, respectively. No decrease in the individual
subunits was observed. Numbers on the right indicate the molecular weight in kilodaltons.
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bly transfected cell line of oligodendroglia origin (Richter-
Landsberg and Heinrich, 1996) overexpressing the longest
human tau isoform. Wild-type OLN-93 cells do not express tau,
and tau transfection per se did not cause the induction of HSPs.
The cells were treated with OA at a concentration that specifically
leads to the inhibition of PP2A (Favre et al., 1997). Treatment
with OA (20 nM) resulted in the hyperphosphorylation of tau, as
detected by the phosphorylation-specific antibody tau-1, 12E8,
and PHF-1 (Fig. 2). The MAb tau-1 recognizes unphosphory-
lated tau; hence, a decrease in tau-1 immunoreactivity reflects an
increase in phosphorylation. The phosphorylation-dependent
MAbs 12E8 and PHF-1 detect tau phosphorylated at Ser262 and
Ser396/404, respectively. After treatment with OA, neither
HSP70 nor B-crystallin was induced, and the expression of the
constitutive HSC70 isoform was unchanged in all samples (Fig.
2). However, expression of HSP32, a small HSP with enzymatic
activity also known as heme oxygenase-1, was induced (Fig. 2).
HSP32 is a sensor and regulator of many forms of oxidative stress
(Schipper, 2000) and, in oligodendrocytes, is highly inducible by
hydrogen peroxide (Goldbaum and Richter-Landsberg, 2001).
Hyperphosphorylation of tau in OLN-t40 cells led to a de-
crease in MT-binding activity (Fig. 3). MTs were isolated from
cells after stabilization with taxol, and the amount of tau was
determined in the pellet (MT fraction) and supernatant (soluble
fraction) by Western blot analysis and compared with the immu-
noreactivity of tubulin in the same fractions. As shown in Figure
3, after the 24 hr treatment, the amount of tau bound to MT,
recovered from the pellet, decreased with higher concentrations
of OA and was maximal at 20 nM. Treatment with LiCl (20 mM),
which is an inhibitor of glycogen synthase kinase 3 (GSK3)
leading to tau dephosphorylation (Hong et al., 1997), in contrast
led to an increase in the binding of tau to MTs as reflected by the
high proportion of tau in the pellet (Fig. 3). The LiCl-induced
alteration in tau phosphorylation causes the appearance of a
prominent double band (Fig. 3).
To assess whether aggregates are formed in OLN-t40 cells,
indirect immunofluorescence was performed using the poly-
clonal phosphorylation-independent antibody to tau (17026)
followed by thioflavin-S staining. The treatment with OA caused
severe morphological changes (e.g., the cytoplasmic processes
were retracted); however, cells did not die by programmed cell
death, as indicated by the absence of an apoptotic DNA ladder
(data not shown) and the integrity of the cellular nuclei (Fig. 4).
In addition, in OLN-t40 cells, tau is abundant in both the cell
soma and processes (Fig. 4). In control cells and after 3 hr treat-
ment with OA (20 nM), thioflavin-S-positive deposits were rare
(1% of the cells). After treatment for 6 hr, thioflavin-S-positive
aggregates containing tau formed in 10% of the cells (Fig. 4).
However, these aggregates were only transiently expressed and,
after 24 hr, cultures resembled the untreated controls. Thus, OA
led to the hyperphosphorylation of tau, a decrease in MT-binding
capability, and the transient induction of intracytoplasmic inclu-
sions, suggesting that the proteasomal machinery of the cells was
capable of degrading the insoluble proteinaceous material. In this
study, we tested whether an impairment of the proteasomes con-
tributes to or stabilizes inclusion body formation.
Inhibition of proteasomes by MG-132 induces the
accumulation of HSPs and inhibits tau degradation
MG-132 belongs to a class of recently developed peptide protea-
somal inhibitors (Lee and Goldberg, 1998), and treatment of
OLN-t40 cells with MG-132 inhibited proteasomal activity effec-
tively. After 4 hr incubation with 0.5 M MG-132, the proteaso-
mal activity was reduced to 40% of untreated controls and
almost completely inhibited with 10 M MG-132 (Fig. 5a). This
treatment, as analyzed by immunoblotting, did not impair the
proteasomal subunits 20S and 20S, even after 18 hr of incuba-
tion with MG-132 at a concentration of 10 M (Fig. 5b). Hence,
loss of proteasome activity was not attributable to decreased lev-
els of proteasome subunits. MG-132 caused the induction of
HSPs, specifically HSP70, HSP32, and B-crystallin, in a time-
and concentration-dependent manner (Fig. 6). The accumula-
tion of B-crystallin and HSP32 was observed after treatment
with 0.5 M MG-132 (Fig. 6a) and was maximal after 18 hr at a
concentration of 10 M (Fig. 6b). Western blot analysis of cell
extracts also showed that MG-132 could prevent the degradation
of tau proteins and led to an increase in PHF-1 immunoreactivity
without impairing the level of tubulin (Fig. 7). Hence, MG-132 in
OLN-t40 cells leads to an induction of B-crystallin and an im-
pairment of tau proteolysis.
MG-132 stabilizes hyperphosphorylated tau
Exposure of OLN-t40 cells to OA (20 nM) caused a reversible
hyperphosphorylation of tau (Fig. 2). Sixteen hours after removal
of OA, tau phosphorylation resembled the untreated control
(Fig. 8). Comparison of hyperphosphorylated tau after incuba-
tion with OA or MG-132 alone, or OA followed by MG-132 (Figs.
2, 8), demonstrates that MG-132 leads to the specific accumula-
Figure 6. a, b, Induction of heat-shock proteins by MG-132. OLN-t40 cells were treated with
MG-132 at various concentrations for 18 hr ( a) or with 10 M MG-132 for 1–24 hr ( b). Cell
lysates were prepared and subjected to immunoblot analysis using a panel of antibodies against
the following after-heat-shock proteins: HSP90, HSP70, HSP60, HSP40, HSP32, and B-
crystallin. In comparison, the immunoreactivity of -tubulin was determined using MAb anti-
-tubulin. Co, Untreated control.
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tion of hyperphosphorylated tau, detected by 12E8, PHF-1, and
tau-1 antibodies.
OA-induced cytoplasmic inclusions are stabilized by MG-132
and contain hyperphosphorylated filamentous tau
Exposure of OLN-t40 cells to MG-132 (0.5 M; 24 hr) led to the
accumulation of B-crystallin in the perinuclear region; how-
ever, these aggregates were not stained by thioflavin-S. Treatment
with OA alone (24 hr) also did not lead to detectable aggregates
(Fig. 9). In contrast, when cells were treated with OA (20 nM; 6 hr)
first and then subjected to MG-132 (0.5 M) for an additional 18
hr, thioflavin-S-positive aggregates were observed in a cellular
location distinct from the MG-132-induced B-crystallin accu-
mulations (Fig. 9). Quantitative evaluation showed that incuba-
tion with OA (20 nM; 6 hr) followed by MG-132 resulted in 6% of
OLN-t40 cells containing thioflavin-S-positive aggregates.
Hence, MG-132 led to the stabilization of OA-induced aggre-
gates. Additional characterization of the inclusion bodies by in-
direct immunofluorescence staining, using antibodies against tau
or B-crystallin, followed by thioflavin-S staining, demonstrates
that tau and B-crystallin are present in these aggregates (Fig.
10). Furthermore, the inclusions contain phosphorylated tau, as
demonstrated by PHF-1 immunoreactivity (Fig. 10d--f). Double
labeling, using antibodies against B-crystallin and tau, con-
firmed the colocalization of both proteins in aggregate-like inclu-
sions (Fig. 10j--l).
To assess whether the thioflavin-S-positive aggregates contain
tau filaments, immuno-EM was conducted on OLN-t40 cells
treated with OA (20 nM; 6 hr) followed by MG-132 (Fig. 11).
Using DAB plus silver enhancement for immunolabeling with
anti-tau antibody, 30% of the transfected OLN-t40 cells con-
tained tau-positive cytoplasmic aggregates (Fig. 11a), and in
10% of the aggregates, tau-positive staining was localized to
filamentous structures (Fig. 11b,c). Thus, the tau aggregates
found in OLN-t40 cells after OA and MG-132 treatment resem-
ble authentic tau aggregates in the brains of patients with
tauopathies.
Discussion
The importance of glial pathology has become recognized only
recently. Insoluble tau is often more abundant in white matter
than in gray matter (Forman et al., 2002; Zhukareva et al., 2002),
and tau-positive glial inclusions in oligodendrocytes are specifi-
cally prominent in PSP, CBD, and Pick’s disease (Komori, 1999).
Tau pathology in AD is characterized by the occurrence of hyper-
phosphorylated tau predominantly in the intracytoplasmic ag-
gregates of neurons, which are identified by a number of
phosphorylation-dependent antibodies, including PHF-1 (for
review, see Bueé et al., 2000; Lee et al., 2001). The inclusion bodies
found in oligodendrocytes of CBD, PSP, and FTDP-17 brains in
our study also contained PHF-1 immunoreactivity, indicating
the presence of hyperphosphorylated tau. This contrasts with the
GCIs found in white-matter oligodendrocytes of MSA brains,
which are composed primarily of -synuclein and could be im-
munolabeled only with phosphorylation-independent tau anti-
Figure 7. MG-132 inhibits tau proteolysis. OLN-t40 cells were incubated with 10 M MG-
132 for 1–24 hr, and cell lysates were prepared. Immunoblot analysis was performed using
phosphorylation-independent tau 17026 antibody reacting with total tau and
phosphorylation-dependent antibodies tau-1 and PHF-1, recognizing nonphosphorylated and
phosphorylated tau proteins, respectively, and MAb anti--tubulin antibodies. MG-132 inhib-
its the formation of proteolytic tau fragments. Co, Untreated control. Figure 8. Hyperphosphorylated tau is stabilized in OLN-t40 cells by MG-132. OLN-t40 cells
were treated with MG-132 alone (MG; 0.5 M; 18 hr), with OA (20 nM; 6 hr) followed by MG-132
(0.5 M; 18 hr) in the absence of OA (OA–MG), or with OA (20 nM; 6 hr) followed by a recovery
period of 18 hr in the absence of OA (OA). Co, Untreated control. Cell lysates were analyzed by
immunoblot procedure using a panel of phosphorylation-dependent and phosphorylation-
independent tau antibodies, antibodies against HSPs, and antibodies against tubulin, as de-
scribed in Figure 2.
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bodies or MAb tau-1, recognizing unphosphorylated tau (Cairns
et al., 1997; Tu et al., 1998).
The binding activity of tau to MTs is regulated by phosphor-
ylation, and hyperphosphorylation at certain sites impairs the
binding of tau to MTs and destabilizes the MT network (Johnson
and Hartigan, 1998; Hong et al., 2000). The phosphorylation
state of tau is balanced by the activities of protein kinases, includ-
ing cyclin-dependent kinase cdk5, p42 and p44 MAP kinases
[ERK1 (extracellular signal-regulated kinase 1), ERK2], GSK-3,
and protein phosphatases. PP2A and PP2B efficiently dephos-
phorylate tau in vitro. The selective inhibition of PP2A by OA
induced AD-like phosphorylation and accumulation of tau in the
mammalian brain (Gong et al., 2000). In AD brains, a decrease in
PP2A activity (Gong et al., 1995) and mRNA expression was
detected (Vogelsberg-Ragaglia et al., 2001). The molecular mech-
anisms underlying GCI formation and tau accumulation in glial
cells are primarily unknown.
The data presented here, using a cell culture model system,
demonstrate that inhibition of PP2A by OA in oligodendroglial
cells overexpressing the longest human tau isoform leads to tau
hyperphosphorylation and a decrease in the binding of tau to
MTs. Simultaneously, tau- and B-crystallin-positive aggregates
can be detected in the cell soma that stain with thioflavin-S and
filamentous aggregated tau. However, these aggregates are re-
moved within 24 hr, which points to an efficient unimpaired
proteolytic system. When the proteasomal machinery was inhib-
ited by MG132 after OA treatment, the aggregates were stabilized.
Hence, although hyperphosphorylation contributes to patholog-
ical aggregation, an age-related proteasomal dysfunction might
potentiate this effect. The proteasomal degradation of tau, possi-
bly without the requirement of ubiquitination, has been demon-
strated recently (David et al., 2002). A loss of proteasomal func-
tions occurs in aging animals (for review, see Keller et al., 2002),
and proteasome inhibition might play a role in neurodegenera-
tion (Keller et al., 2000). As shown in the present study, tau pro-
teolysis is inhibited, and HSPs are induced when the degradative
process is blocked by proteasome inhibitors. The induction of
HSPs by proteasome inhibitors has been described previously in
other cell systems (Lee and Goldberg, 1998). For example, pro-
teasome inhibition by MG-132 induced the accumulation and
recruitment of HSP27 and B-crystallin to aggresomes in U373
MG cells (Ito et al., 2002). In OLN-t40 cells, B-crystallin was
induced in a time- and concentration-dependent way and trans-
located to the perinuclear region of the cells. Yet, these deposits
did not stain with thioflavin-S. Thioflavin-S-positive inclusions
were observed only after treatment with OA and when OA-
treated cells were subsequently incubated with MG-132. This in-
dicates that tau hyperphosphorylation and the detachment of
these forms of tau from the MTs is a prerequisite for the forma-
tion of fibrillary inclusions. In contrast, our data indicate that tau
hyperphosphorylation alone is not sufficient to induce perma-
nent aggregates. Hyperphosphorylation followed by proteasomal
inhibition is necessary for the formation of stable aggregates,
which contain hyperphosphorylated tau and B-crystallin.
Figure 9. Accumulation of cytoplasmic inclusions by proteasome inhibition after OA treat-
ment. OLN-t40 cells were subjected to 0.5 M MG-132 for 24 hr (d–f ), to 20 nM OA for 24 hr
( g–i), or to 20 nM OA for 6 hr followed by 0.5 M MG-132 for 18 hr in the absence of OA ( j–l ).
Indirect immunofluorescence was performed using MAb anti-B-crystallin (red) followed by
thioflavin-S staining (green). For nuclear staining (blue), DAPI was included in the mounting
medium. a– c, Untreated control. a, d, g, j, B-crystallin (red). b, e, h, k, Thioflavin-S (green). c,
f, i, l, Overlay with DAPI. Scale bar, 20 m.
Figure 10. Cytoplasmic inclusions contained tau and B-crystallin. OLN-t40 cells were
treated with 20 nM OA for 6 hr, followed by 0.5 M MG-132 for 18 hr in the absence of OA. Cells
were subjected to indirect immunofluorescence using polyclonal tau antibody 17026 (a– c),
MAb PHF-1 (d–f ), or MAb B-crystallin ( g–i), followed by thioflavin-S staining (green). To
demonstrate tau and B-crystallin colocalization, double labeling was performed using poly-
clonal tau antibody 17026 (red) and B-crystallin (green) (j–l). For nuclear staining (blue),
DAPI was included in the mounting medium. Scale bar, 10 m.
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We also show that tau-positive oligodendrocytes bearing
coiled bodies from patients with tauopathies (i.e., PSP, CBD, and
FTDP-17) are positive for B-crystallin. So far, the association of
B-crystallin has been identified repeatedly only in GCIs in oli-
godendrocytes from patients with MSA (for review, see Chin and
Goldman, 1996; Komori, 1999). B-crystallin belongs to the
group of small HSPs, which interact with the cytoskeleton in
normal cells and play a role in inclusion body formation (Head
and Goldman, 2000). In the CNS, B-crystallin is primarily ex-
pressed in oligodendrocytes (Head and Goldman, 2000; Gold-
baum and Richter-Landsberg, 2001). It exerts cytoprotective
functions and is involved in the modulation of intermediate fila-
ment organization under conditions of physiological stress and
neurodegenerative disease (Head and Goldman, 2000). In AD
brains, the appearance of B-crystallin in neurons has been
linked to later severe stages of pathogenesis, when abundant tau-
positive neurofibrillary tangles are observed (Mao et al., 2001). It
is also a major component of Rosenthal fibers, which are the
characteristic inclusion bodies found in astrocytes of patients
with Alexander’s disease (Head and Goldman, 2000). The intro-
duction of B-crystallin into inclusion-bearing astrocytes over-
expressing glial fibrillary acidic protein (GFAP) caused the dis-
persion of GFAP accumulations but not the appearance of
Rosenthal fibers (Koyama and Goldman, 1999). Hence, B-
crystallin might initially be a protective means against interme-
diate filament disorganization, and inclusion body formation is a
later stage of the pathogenic response.
Oligodendrocytes do not contain intermediate filaments but
have a very prominent MT-system (Richter-Landsberg, 2001).
Also, the cell line used in this study is devoid of an intermediate
filament system (Richter-Landsberg and Heinrich, 1996). An af-
finity of B-crystallin for MTs has been suggested previously
(Arai and Atomi, 1997), and agents that promote the disassembly
of MTs induce its expression (Kato et al., 1996). HSPs constitute
the major cellular defense against unfolded proteins (for review,
see Sherman and Goldberg, 2001), and their expression is con-
nected to protection of neural cells (for review, see Richter-
Landsberg and Goldbaum, 2003). In oligodendrocytes, B-
crystallin is effectively upregulated under conditions of oxidative
and heat stress, which eventually lead to the onset of programmed
cell death (Goldbaum and Richter-Landsberg, 2001). It seems
likely that B-crystallin is involved in the protection of the cy-
toskeletal organization in oligodendrocytes and, as a chaperone,
is recruited to prevent tubulin and tau aggregation. However,
when the damage is beyond repair, protection fails and HSPs
most likely contribute to degenerative processes and cell death.
In summary, cytoplasmic glial inclusions are a common fea-
ture of a variety of neurodegenerative diseases. Prominent oligo-
dendroglia tau pathology occurs in PSP, CBD, Pick’s disease, and
FTDP-17. At least a subset of the inclusion bodies in oligoden-
droglia, as shown in the present study, also contains the small
HSP B-crystallin, indicating that molecular chaperones partic-
ipate in the cellular responses to stressful situations that cause
protein aggregation and the assembly into aggresome-like struc-
tures. Tau hyperphosphorylation and proteasomal impairment
contribute to aggregate formation in oligodendroglial cells, sug-
gesting that alterations of the proteasomal system, which might
occur during aging, are involved in the neuropathological events
leading to degeneration.
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